Biopharmaceutical developers reported critical Phase II milestones for mRNA-based personalized cancer vaccines this week.
Targeted Delivery Mechanisms
Lipid nanoparticle delivery enhancements reduced off-target liver toxicity by 35% while increasing therapeutic absorption.